Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. hormone active
Show results for
Products

Companies

News
Articles

Refine by
Date

  • Older

Hormone Active Articles & Analysis

8 news found

Antengene Announces NDA Submission for XPOVIO in Macau,China, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma

Antengene Announces NDA Submission for XPOVIO in Macau,China, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma

By blocking the nuclear export protein XPO1, XPOVIO® can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. XPOVIO® delivers its antitumor effects through three mechanistic pathways: 1) exerting antitumor effects by inducing the intranuclear ...

ByAntengene Corporation Limited


Pronalyse’s Fusion Protein Characterization Service Aids in the Drug Development Process

Pronalyse’s Fusion Protein Characterization Service Aids in the Drug Development Process

Fusion protein refers to a new type of synthetic protein by fusing a certain biologically active functional protein molecule with other natural proteins (fusion partners) using technologies such as genetic engineering. Functional protein molecules are usually endogenous ligands (or corresponding receptors), such as cytokines, growth factors, hormones, enzymes, or ...

ByCreative Proteomics


Antengene Announces XPOVIO Regulatory Approval in Taiwan for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma

Antengene Announces XPOVIO Regulatory Approval in Taiwan for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma

By blocking the nuclear export protein XPO1, XPOVIO® can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. XPOVIO® delivers its antitumor effects through three mechanistic pathways: 1) exerting antitumor effects by inducing the intranuclear ...

ByAntengene Corporation Limited


New phase of breast cancer treatment trial provides fresh hope for patients with incurable disease

New phase of breast cancer treatment trial provides fresh hope for patients with incurable disease

The latest research builds on the 2019 FAKTION trial based on the use of capivasertib, an investigational breast cancer drug developed by AstraZeneca that blocks the activity of a protein called AKT that has been shown to contribute to resistance to hormone therapy. ...

ByMediWales


Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

(NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, initially targeting pediatric growth hormone deficiency, today announced a collaboration with Laura Dichtel, MD of Massachusetts General Hospital to evaluate the orally administered growth hormone (GH) secretagogue, LUM-201, in Nonalcoholic Fatty Liver Disease ...

ByLumos Pharma


ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study with Letrozole, Palbociclib and Onapristone ER

ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study with Letrozole, Palbociclib and Onapristone ER

Extended release Onapristone (Onapristone ER) is a progesterone receptor (PR) antagonist that inhibits hormone-mediated PR activation and stabilizes PR association with compressors, resulting in an antineoplastic effect when applied alone or in combination with antiestrogen therapy to breast cancer cells in vitro (1). ...

ByContext Therapeutics Inc.


EPA Uses Cutting-Edge Technology to Evaluate Chemicals for Human Hormone Impacts

EPA is proposing to use ground-breaking tools developed in the ToxCast program to improve testing for chemicals that have the potential to disrupt hormone function in the human body. EPA uses automated chemical screening technologies to rapidly and simultaneously perform tests on thousands of chemicals and feed the results into computational models to predict ...

ByUS EPA - Environmental Protection Agency


Chemical widely used in antibacterial hand soaps may impair muscle function

The investigators performed several experiments to evaluate the effects of triclosan on muscle activity, using doses similar to those that people and animals may be exposed to during everyday life. ...

ByNational Institute of Environmental Health Sciences (NIEHS)

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT